OPSENS REPORTS Q4 and FY2018 RESULTS – RECORD ANNUAL REVENUE SURPASS $24 M AND RECORD QUARTERLY FFR REVENUES AT $4.1 M
28 November 2018Quebec City, Quebec, November 28, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the fourth quarter and fiscal year ended August 31, 2018. Highlights for the quarter and for the year Fractional Flow Reserve (“FFR”) revenues reach $4.1 M in the fourth quarter of 2018 compared with $2.8…
OPSENS RECEIVES HEALTH CANADA APPROVAL FOR dPR INTENDED FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST
27 November 2018Quebec City, Quebec, November 27, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) announced today that it has obtained approval from Health Canada to market its dPR Proprietary Resting Index, which measures intracoronary pressure and establishes a diagnosis with the heart at rest to guide the treatment of patients with coronary heart disease. dPR stands for Diastolic…
OPSENS – FIRST USE OF dPR FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST
8 November 2018Quebec City, Quebec, November 8, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) announces that its Diastolic Pressure Ratio called dPR, has been used for the first time by Dr. Hitoshi Matsuo, cardiologist and President of the Gifu Heart Center Japan. The measurement of Fractional Flow Reserve (“FFR”) as a method of assessing intracoronary pressure has gained credibility and popularity…
OPSENS – 50,000 PATIENTS DIAGNOSED WITH THE OPTOWIRE
1 November 2018Quebec City, Quebec, November 1st, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has reached an important milestone with more than 50,000 patients assessed with the OptoWire™, a pressure guidewire used to measure Fractional Flow Reserve (“FFR”) to diagnose and treat cardio vascular disease. The use of pressure guidewires to measure FFR for…